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Abstract
Background Cancer screening has contributed to downward trends
in cancer mortality, but is also associated with adverse eﬀects, which
highlights the importance of promoting the participation based on
informed decisions.
Objectives We aimed to describe the use of cancer screening (either
in organized programmes or as opportunistic screening), awareness
of organized programmes and perception of its potential beneﬁts
and adverse eﬀects, depicting possible sex diﬀerences.
Design and methods We evaluated 1624 Portuguese-speaking dwell-
ers, aged between 16 and 79 years, through face-to-face interviews.
To quantify sex diﬀerences, adjusted prevalence ratios and respective
95% conﬁdence intervals were computed using Poisson regression.
Results Among eligible age groups, the lifetime prevalence of screen-
ing for breast and cervical cancers was 89.8 and 71.9%, respectively.
The prevalence was 23.7% for colorectal cancer and no signiﬁcant sex
diﬀerences were observed. Prostate cancer screening was reported by
63.8% of men. Over half of the participants referred that cancers such
as prostate, skin, lung and stomach should be screened for, in addi-
tion to those for which organized programmes are recommended.
Reassurance by negative results was identiﬁed as the main potential
beneﬁt of screening by nearly one-third of men and women. Anxiety
while waiting for results was the most mentioned potential adverse
eﬀect (60.4%); men refer less often this and ﬁnancial costs, although
statistical signiﬁcance of these results was borderline.
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Conclusions This study provides a benchmark to plan and monitor
the eﬀects of awareness-raising interventions, as well as for interna-
tional comparisons across countries with diﬀerent cancer prevention
and control structures.
Introduction
In the last few decades, an increasing number of
deaths due to oncologic diseases has been
observed worldwide,1 and almost 15 million
cancer deaths are expected by 2035.2 In Portu-
gal, just over 24 000 deaths were observed in
2012,2 and, among men, cancer already sur-
passed cardiovascular disease as the leading
cause of years of life lost.3 Additionally, for the
next decades, it is expected a 38% increment in
the overall number of deaths attributable to can-
cer in Portuguese population, with a higher
increase in men than in women (41% vs. 33%),2
if the trends in mortality observed in the last few
years are maintained.
Regardless of the increasing absolute number
of deaths due to cancer, which can be partially
explained by population growth and ageing,4 in
high-income countries, a downward trend in
overall cancer age-standardized mortality rates
has been recently observed.1 This is likely to
reﬂect decreases in the incidence of tobacco-
related cancers,5 and the access to more eﬀective
treatment and improvements on earlier detection
of cancer.6 Nevertheless, cancer screening is
associated with overdiagnosis and overtreat-
ment,7 among other potential adverse eﬀects,
which highlights the importance of promoting
informed decisions regarding the participation
in cancer screening programmes.
Cancer screening can be performed as part of
organized programmes or opportunistically. The
former requires a documented policy where the
targeted population groups, the screening tests
and screening intervals are deﬁned and implies a
team and an administrative structure responsible
for inviting the eligible population, service deliv-
ery, quality assurance and evaluation at the
national or regional level. The latter corresponds
to screening conducted unsystematically, taking
advantage of the contact of the potentially eligi-
ble subjects with the health system.8,9
According to the Council of the European
Union,10 organized programmes for cancer
screening are recommended for breast, cervical
and colorectal cancers. In Portugal, screening
programmes are implemented by each of the
regional health administrations; although the
potentially eligible subjects are identiﬁed through
the primary health-care centres and invited to
participate in the screening programmes for these
cancers, there are diﬀerences in the management,
population coverage and date of onset according
to region and type of cancer.
Organized screening for breast cancer was
started in 1990 and has been gradually expand-
ing to the entire country; in 2012, it was
estimated that approximately two-thirds of the
population was covered. In most regions, the
organized screening targets women aged 45–
69 years, to be screened by mammography
every 2 years.11
For cervical cancer, organized screening was
ﬁrst implemented in 1990; in 2012, just over
40% of the eligible population was covered. In
most regions, organized screening targets
women aged 25–64 years, to be screened by con-
ventional cytology (Pap test) or liquid-based
cytology; complementary testing for human
papillomavirus (HPV) infection is available in
some regions.11 In a clinical norm for diagnosis
and staging of cervical cancer, the Portuguese
Directorate-General of Health recommends that
screening for this type of cancer should be pro-
vided to all women between 25 and 64 years of
age that were not previously screened.12
Organized screening for colorectal cancer
started in 2009; in 2012, only two regions of main-
land Portugal had implemented such programmes,
which translate into 9.3% of the country’s eligible
population being covered. Organized colorectal
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cancer screening targets men and women aged
between 50 and 69 or 70 years, to be tested by a
faecal occult blood test (FOBT) every 2 years.11 In
addition, to increase the opportunistic screening,
the Portuguese Directorate-General of Health rec-
ommends annual prescription of FOBT in all
asymptomatic individuals aged between 50
and 74 years.13
According to guidelines recently issued by
the Portuguese Directorate-General of Health,
opportunistic screening using prostate-speciﬁc
antigen’s evaluation (PSA) may be prescribed to
men who request this examination, after them
being informed about the potential beneﬁts and
risks associated with this procedure.14
In addition to distinct cancer screening recom-
mendations for men and women, sex diﬀerences
regarding cancer knowledge and use of screening
were previously outlined. Women are commonly
described as having higher levels of cancer
awareness,15 providing higher estimates of life-
time risk of cancer,16 and are more worried in
getting cancer than men.17 However, concerning
the adherence to cancer screening, the results are
less consistent, and some studies show that men
may attend cancer screening more frequently
than women, depending on the type of examina-
tion.18 Sex diﬀerences regarding the perception
of facilitators and barriers associated with cancer
screening uptake have also been observed.19,20
Therefore, this study aims to describe the use
of cancer screening, awareness of organized pro-
grammes and perception of its potential beneﬁts
and adverse eﬀects, depicting possible diﬀer-
ences between men and women.
Methods
Study population
The present analysis was based on a national sur-
vey conducted in 2012, aiming to assess
knowledge and health behaviours of the Por-
tuguese population aged between 16 and 79 years.
The study selected a representative sample of
Portuguese-speaking dwellers in mainland Por-
tugal, using a multistage sampling design,
deﬁned according to results of the 2001 Por-
tuguese Census.21 A probabilistic sampling
procedure, stratiﬁed by NUTS II – Territorial
Nomenclature Units for Statistical Purposes,
level II (North, Centre, Lisbon and Tagus Val-
ley, Alentejo and Algarve) and by the number of
inhabitants in geographical units with at least 10
dwellings (<2000, 2000–9999, 10 000–19 999,
20 000–100 000, >100 000), was used to select
150 geographical units, among which a total of
585 starting points were designated for the selec-
tion of households through standard random
route procedures. All of the potentially eligible
dwellers were identiﬁed in each selected house-
hold, and only the one whose previous birthday
was closest to the date of the contact was invited
to participate; a total of 1624 valid interviews
were obtained (response rate: 70.8%).
Data collection
Participants were evaluated through face-to-face
interviews, using a structured questionnaire.
The questions regarding the use of screening
were preceded by a brief explanation highlight-
ing that the questions refer to tests performed in
the absence of disease symptoms, that is, have
been carried out routinely aiming to early detec-
tion. The use of cancer screening at least once
during the participants’ lives was assessed for
breast (among women aged ≥30 years: Did you
ever perform a mammography testing for breast
cancer screening?), cervix (among all women:
Did you ever use cervical cancer screening, i.e. the
Pap smear test, on a routine basis?), colon and
rectum (among women and men aged ≥40 years:
Did you ever perform a FOBT for colorectal can-
cer screening, on a routine basis?; Did you ever
perform a colonoscopy for colorectal cancer
screening, on a routine basis?), and prostate
[among men aged ≥40 years: Did you ever use
prostate-speciﬁc antigen (PSA) testing (blood
analysis for prostate cancer screening), on a rou-
tine basis?; Did you ever use prostate cancer
screening, i.e. digital rectal examination (DRE),
on a routine basis?]. To estimate the lifetime
prevalence of use of screening for each of these
cancers, we considered only the age groups that
should be screened for, according to the screen-
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ing policy adopted in Portugal: breast – 45–69
years11; cervix – 25–64 years11,12; colorectal –
50–74 years11,13; prostate – 55–69 years.14
Participants were also asked to indicate
whether speciﬁc cancers should be screened for
after a certain age, including those with national
programmes, such as breast, cervical and
colorectal, and other frequent cancers for which
there is no organized screening, namely prostate,
stomach, lung and skin (Which of the following
cancers should be screened for, after a certain
age? – for each cancer, possible answers were
‘yes’, ‘no’, ‘do not know’ and ‘did not answer’;
for data analysis, the option ‘do not know’ and
‘did not answer’ was coded as ‘no’).
The perception of potential beneﬁts of cancer
screening was evaluated through selection of the
main beneﬁt (Which is the main beneﬁt of partici-
pating in cancer screenings?), from the following
list: ‘earlier detection’, ‘more eﬀective treatment’
and ‘knowledge of not having the disease’. For
several potential adverse eﬀects of screening,
participants were asked to indicate whether they
fear that these problems may occur after partici-
pation in cancer screening (Do you fear that each
of the following eﬀects may occur after a cancer
screening? – possible answers were ‘yes’, ‘no’, ‘do
not know’ and ‘did not answer’; for data analy-
sis, the option ‘do not know’ and ‘did not
answer’ was coded as ‘no’), namely ‘pain or dis-
comfort due to medical examinations’, ‘being
anxious while waiting for the results’, ‘the test
shows that you are ill when you are not’, ‘the test
does not show that you are ill when you actually
are’, ‘undergoing unnecessary treatments’, ‘an-
ticipated diagnosis of an incurable disease’ and
the ‘ﬁnancial costs for yourself (e.g. tra-
vel expenses)’.
Statistical analysis
Statistical analyses were performed using
STATA version 11.1 (College Station, TX,
USA, 2009). To estimate the associations
between sex and use, knowledge and perceptions
about cancer screening, we computed adjusted
prevalence ratios (PR) and respective 95% conﬁ-
dence intervals (95% CI) using Poisson
regression models, including age and educa-
tional level. The product of design and
population weights was also computed and used
in all analyses; the former were used to compen-
sate for the unequal probability of selection, and
the latter, to correct the discrepancy between
sample composition and the Portuguese popula-
tion regarding sex, age, education, marital status
and NUTS II distribution and size of the geo-
graphical units.
Ethical approval
This survey was approved by the Ethics Com-
mittee of the University of Porto (33/CEUP/
2012), and all participants provided written
informed consent.
Results
The sample included a similar proportion of
men and women, mostly from the North and
South regions of mainland Portugal. Subjects
younger than 30 years corresponded to less than
30% of the sample, with a higher proportion
among men, and participants aged 70–79 years
were nearly 9%, with a higher proportion
among women. Just over 45% of women and
nearly 40% of men had 0–4 years of schooling,
whereas the proportion of those with more than
12 years of schooling was higher among women
(16.0% vs. 11.7%) (Table 1).
Regarding the lifetime prevalence of cancer
screening among eligible age groups, 89.8%
(95% CI: 85.7–93.8) of women between 45 and
69 years reported a previous use of mammogra-
phy and, among women aged 25–64 years,
71.9% (95% CI: 66.5–77.3) had a screening cer-
vical cytology before. Regarding colorectal
cancer screening, the lifetime prevalence among
participants aged 50–74 years was 23.7% (95%
CI: 19.4–27.9), with no statistically signiﬁcant
sex diﬀerences (PR = 1.14; 95% CI: 0.81–1.59).
Among men aged 55–69 years, 63.8% (95% CI:
54.9–72.8) reported to have been screened for
prostate cancer (Fig. 1).
Approximately 90% of participants consid-
ered that screening was recommended for
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prostate, breast and cervix cancers (90.1, 89.6
and 86.0%, respectively), and a lower propor-
tion of the participants identiﬁed colorectal
(76.2%), lung (62.3%), stomach (60.5%) or skin
(50.6%) cancers, as conditions that should be
screened for after a speciﬁc age. There were no
statistically signiﬁcant sex diﬀerences, except for
men reporting less frequently that screening for
breast (PR = 0.92; 95% CI: 0.88–0.97) and cervix
(PR = 0.90; 95% CI: 0.86–0.95) cancers should
be performed after a certain age (Fig. 2).
Concerning the potential beneﬁt of cancer
screening, a higher proportion of respondents
identiﬁed the early detection of cancer as the
main advantage (58.6%), followed by the reas-
surance by negative results (31.4%) and more
eﬀective treatment (10.0%), with no signiﬁcant
statistical diﬀerence between sexes. The identiﬁ-
Table 1 Characteristics of participants
(n = 1624) Women Men
Non-weighted % Weighted % Non-weighted % Weighted %
All participants 61.4 50.3 38.6 49.7
Region of residence (NUTS II)*
North 40.7 40.4 39.6 39.9
Centre 23.6 18.3 18.8 17.4
South† 35.8 41.3 41.5 42.6
Age (years)
<30 11.7 25.4 18.5 29.9
30–39 12.8 15.5 15.3 17.8
40–49 14.6 19.5 14.4 18.7
50–59 18.5 15.3 15.6 13.4
60–69 23.2 13.4 20.3 12.4
70–79 19.1 10.8 15.8 7.8
Education (years)
0–4 53.2 45.3 42.0 39.7
5–9 16.0 14.6 22.5 22.2
10–12 17.4 24.0 22.4 26.4
>12 13.4 16.0 13.1 11.7
*NUTS II, Territorial Nomenclature Units for Statistical Purposes, level II.
†Includes the regions of Lisbon and Tagus Valley, Alentejo and Algarve.
Percentages may not total 100 due to rounding.
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Figure 1 Prevalence of cancer screening utilization during lifetime, among Portuguese women and men. *Age and education-
adjusted prevalence ratio (men vs. women) = 1.14 (95% CI: 0.81–1.59). Use of cancer screening was only considered among the
following age groups: Breast (mammography) – 45–69 years of age (only women)11; Cervix (cervical cytology testing) – 25–
64 years of age (only women)11,12; Colorectal (faecal occult blood test and/or colonoscopy) – 50–74 years of age (all)11,13;
Prostate (prostate-specific antigen and/or digital rectal examination) – 55–69 years of age (only men).14
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cation of potential adverse eﬀects of cancer
screening ranged between 41.0%, for overtreat-
ment, and 60.4%, for anxiety while waiting for
results. Men were less likely to refer all potential
adverse eﬀects, particularly anxiety while wait-
ing for results (PR = 0.89; 95% CI: 0.79–1.00)
and ﬁnancial costs (PR = 0.86; 95% CI:
0.74–1.00), although the statistical signiﬁcance
of these results was borderline (Table 2).
Discussion
The lifetime prevalence of screening varied
widely between the three cancers with organized
screening programmes, which are likely to reﬂect
the marked asymmetries in their population
coverage across regions and time of implementa-
tion, as well as inequalities in the access to
opportunistic screening. Organized programmes
for breast and cervical cancers screening were
the ﬁrst to be implemented in Portugal, but they
still are not available for all the eligible popula-
tion.11 Nevertheless, two previous studies
showed high prevalence of screening in regions
with no organized programme for breast 22 or
cervical cancer,23 which may reﬂect an easy
access to opportunistic screening in these
regions. Although the early detection of cancer
by female breast mammography and cervical
cytology testing contribute to an overall higher
frequency of screening among women, this does
not reﬂect inequalities in the access to screening
according to sex because these cancers aﬀect
only women.
Organized screening programmes for col-
orectal cancer have only recently begun, and,
in 2012, less than 10% of the population was
covered.11 Furthermore, examinations for
screening colorectal cancer, specially colono-
scopy, are frequently perceived as painful,
Breast
Cervix
Colorectal
ProstateStomach
Lung
Skin
20
40
60
80
100
Women Men
Men vs. women: 89.4% vs. 90.8%
PR = 0.99 (95% CI:0.94–1.03)*
Men vs. women: 86.2% vs. 93.0%
PR = 0.92 (95% CI:0.88–0.97)*
Men vs. women: 81.5% vs. 90.4%
PR = 0.90 (95% CI:0.86–0.95)*
Men vs. women: 74.4% vs. 78.0%
PR = 0.95 (95% CI:0.87–1.04)*
Men vs. women: 49.4% vs. 51.8%
PR = 0.95 (95% CI:0.84–1.08)*
Men vs. women: 60.7% vs. 60.2%
PR = 1.01 (95% CI:0.90–1.13)*
Men vs. women: 60.7% vs. 63.9%
PR = 0.94 (95% CI:0.85–1.05)*
Figure 2 Proportion of Portuguese women and men that identified cancers for which screening should be warranted. CI,
confidence interval; PR, prevalence ratio. *Adjusted for age and education level.
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leading to anxiety, discomfort, feelings of vul-
nerability and embarrassment.24 These facts
may contribute to explain the low prevalence
of this type of screening observed in our study,
despite the high proportion of participants
mentioning colorectal as a cancer that should
be screening for.
Although population-based prostate cancer
screening is not recommended, the high preva-
lence of this cancer,2 with survivors sharing their
experience with their social network, and the
focus given by mass-media to prostate cancer,25
may contribute to our observation of nearly
two-thirds of men reporting to have undergone
opportunistic prostate cancer screening. This
prevalence is close to that of women being
screened for cervix cancer and is much higher
than the lifetime prevalence of colorectal cancer
among men and women, in the corresponding
eligible age groups.
In the present study, even cancers for which
screening is not recommended, including pros-
tate or lung, were frequently mentioned as
cancers that should be screened for, drawing
attention to patients’ educational and informa-
tional needs. Previous studies demonstrated a
general population0s enthusiasm regarding can-
cer screening 26 and a trend towards increasing
use of sophisticated technologies for detection of
asymptomatic diseases at early stages.27 The lat-
ter ﬁnding may also underlie the recognition of
early detection as the main advantage of screen-
ing, both among men and women. The fact that
we did not ﬁnd sex diﬀerences regarding the ben-
eﬁts of cancer screening is also in accordance
with prior ﬁndings, showing that men and
women are aligned concerning the beneﬁts but
not in relation to the barriers for screening
uptake.19 On the other hand, one-third of partic-
ipants valued the fact that screening may allow
the reassurance of negative results, which needs
to be taken into account when providing bal-
anced information regarding the beneﬁts and
harms that may be expected from screening by
the potential participants.
Screening for oncologic diseases is not void of
risks, including overdiagnosis and overtreat-
ment.7 However, these adverse eﬀects were the
least reported by our participants. In fact, over-
diagnosis is a concept diﬃcult to understand,
and its acceptability is variable according to the
type of cancer, people’s age and educational
level, but a previous study did not show diﬀer-
ences between men and women.28 Additionally,
information concerning cancer screenings avail-
able in magazine articles, websites and
information brochures used for cancer screening
invitation is most of the times incorrect or
incomplete, and the beneﬁts of screening are
over-reported compared with the harms.25,29,30
The fact that anxiety while waiting for the results
was the main reported disadvantage of cancer
screening may also reﬂect the societal risk port-
folio that rank threats and harms hierarchically
taking into account the cultural norms.31 In fact,
there is a cultural perception of cancer as a dis-
ease that is incurable, painful and with diﬃcult
treatment,32 which may cause anxiety for the
Table 2 Perception of potential benefits and adverse effects
of cancer screening according to sex
Proportion of
participants
identifying each
potential benefit or
adverse effect of
cancer screening (%)
PR (95% CI)*All Women Men
Potential benefits
Earlier
detection or
more effective
treatment†,‡
68.6 68.0 69.3 1.02 (0.92–1.12)
Potential adverse effects
Anxiety while
waiting for
results
60.4 63.9 56.9 0.89 (0.79–1.00)
Anticipated
diagnosis
52.1 53.9 50.3 0.93 (0.81–1.07)
Pain or
discomfort
51.9 52.7 51.2 0.97 (0.85–1.11)
Financial costs 44.9 48.1 41.7 0.86 (0.74–1.00)
False positives 43.6 47.1 40.0 0.85 (0.72–1.01)
False negatives 42.7 46.3 38.9 0.85 (0.71–1.02)
Overtreatment 41.0 41.9 40.2 0.97 (0.82–1.15)
CI, confidence interval; PR, prevalence ratio.
*Adjusted for age and education level.
†vs. knowledge of not having the disease.
‡Excluding 2.5% of participants that did not know/answer.
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screening results. This ﬁnding also highlights the
importance of deﬁning a short waiting time
between the diﬀerent steps of screening as indi-
cators to be evaluated in organized programmes.
Furthermore, it was previously reported that
women have more medical visits,33 as well as
higher levels of cancer awareness,15 perception
of lifetime risk of cancer 16 and cancer worry.17
These ﬁndings, in addition to the highest cover-
age of national screening programmes targeting
only women, may contribute to higher levels of
perceived adverse eﬀects of cancer screening
found among them, particularly anxiety and
ﬁnancial costs, although the associations
observed were not statistically signiﬁcant. Previ-
ous studies have also shown that men tended to
underreport medical and psychological symp-
toms such as pain and emotional distress
focusing predominantly on the external and
material consequences of diseases 34 and that
may be willing to receive less information on
cancer screening than women.20
This study was based on a representative sam-
ple of Portuguese population, evaluated using
standardized methods. Nevertheless, there are
some limitations that should be highlighted. The
data for the present analysis were self-reported,
which may have contributed for an overestima-
tion of the use of cancer screening. According to
prior reports, the estimates retrieved from self-
report data are frequently inﬂated,35 probably
due to recall, acquiescence or social desirability
biases,36,37 as well as diﬃculties in distinguishing
between medical exams performed for cancer
screening and those for diagnosis and surveil-
lance. Additionally, it is not possible to
distinguish cancer screening performed within
an organized programme or opportunis-
tic screening.
The high proportion of subjects identifying
the cancers that should be screened for, includ-
ing prostate cancer, for which no organized
screening is warranted, as well as potential
adverse eﬀects of cancer screening being selected
by most participants, may be related with the
use of prompted questions. In fact, a previous
study has shown that this type of question is
associated with higher cancer-speciﬁc knowl-
edge when compared with unprompted
(recall) conditions.38
Our study is also limited by its cross-sectional
design, as health-related knowledge can be asso-
ciated with adherence to screening, but
participation in cancer screening can also act as
a ‘teachable moment’, contributing to improve
knowledge on cancer screening, as well as to
modulate the perception of its beneﬁcial and
adverse eﬀects.
The external validity of our ﬁndings may be
limited to some extent due to the speciﬁcities of
the Portuguese setting regarding the universal
coverage of the National Health Service,
ﬁnanced essentially by taxes. This may contribute
to reduce inequalities in the access to health care,
even when organized screening is not reaching
the whole eligible population, in addition to the
local cultural norms that may inﬂuence the use of
cancer screening by men and women. However,
our results provide a benchmark for comparisons
regarding overall use of screening, as well as sex
diﬀerences, across countries with distinct types of
health-care systems and cultural speciﬁcities, and
at diﬀerent stages of implementation of orga-
nized screening,39 that may bring them closer or
more distant from the Portuguese population.
Such comparisons may contribute to understand
the potential impact of the implementation of
organized screening in the prevention and con-
trol of cancer, in reducing inequalities and in the
eﬃcient use of resources, taking into account that
it may depend on the extent to which opportunis-
tic screening is already taking place.
Conclusions
The present study shows no substantial sex dif-
ferences in the use of screening, except for those
resulting from the fact that breast and cervical
cancer screening apply only to women and pros-
tate only to men, or regarding the potential
beneﬁts and adverse eﬀects of screening. It pro-
vides a benchmark to plan and monitor the
eﬀects of awareness-raising interventions, as well
as for international comparisons across coun-
tries with diﬀerent levels of implementation of
cancer prevention and control structures.
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